Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Transplantation, Urology & Nephrology, chronic kidney disease-mineral and bone disorder, kidney transplantation, parathyroid hormone, renal osteodystrophy, vitamin D, SERUM 25-HYDROXYVITAMIN D, RANDOMIZED CONTROLLED-TRIAL, J-SHAPED ASSOCIATION, D-BINDING PROTEIN, CLINICAL-PRACTICE RECOMMENDATIONS, ALL-CAUSE MORTALITY, QUALITY-OF-LIFE, SECONDARY HYPERPARATHYROIDISM, HEMODIALYSIS-PATIENTS, DOUBLE-BLIND, chronic kidney disease–mineral and bone disorder, Humans, Kidney Transplantation, Vitamin D, Child, Adult, Renal Insufficiency, Chronic, Vitamin D Deficiency, Renal Dialysis, Chronic Kidney Disease-Mineral and Bone Disorder, Consensus, Dietary Supplements, Europe, 1103 Clinical Sciences, 3202 Clinical sciences

Abstract:

Vitamin D deficiency is common in patients with chronic kidney disease (CKD) and associates with poor outcomes. Current clinical practice guidelines recommend supplementation with nutritional vitamin D as for the general population. However, recent large-scale clinical trials in the general population failed to demonstrate a benefit of vitamin D supplementation on skeletal or non-skeletal outcomes, fueling a debate on the rationale for screening for and correcting vitamin D deficiency, both in non-CKD and CKD populations. In a collaboration between the European Renal Osteodystrophy initiative of the European Renal Association (ERA) and the European Society for Paediatric Nephrology (ESPN), an expert panel performed an extensive literature review and formulated clinical practice points on vitamin D supplementation in children and adults with CKD and after kidney transplantation. These were reviewed by a Delphi panel of members from relevant working groups of the ERA and ESPN. Key clinical practice points include recommendations to monitor for, and correct, vitamin D deficiency in children and adults with CKD and after kidney transplantation, targeting 25-hydroxyvitamin D levels >75 nmol/l (>30 ng/ml). Although vitamin D supplementation appears well-tolerated and safe, it is recommended to avoid mega-doses (≥100 000 IU) and very high levels of 25 hydroxyvitamin D (>150-200 nmol/l, or 60-80 ng/ml) to reduce the risk of toxicity. Future clinical trials should investigate the benefit of vitamin D supplementation on patient-relevant outcomes in the setting of vitamin D deficiency across different stages of CKD.